Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].


Autoria(s): Panchaud A.; Weisskopf E.; Winterfeld U.; Baud D.; Guidi M.; Eap C.B.; Csajka C.; Widmer N.
Data(s)

2014

Resumo

Following the thalidomide tragedy, pharmacological research in pregnant women focused primarily on drug safety for the unborn child and remains only limited regarding the efficacy and safety of treatment for the mother. Significant physiological changes during pregnancy may yet affect the pharmacokinetics of drugs and thus compromise its efficacy and/or safety. Therapeutic drug monitoring (TDM) would maximize the potential effectiveness of treatments, while minimizing the potential risk of toxicity for the mother and the fetus. At present, because of the lack of concentration-response relationship studies in pregnant women, TDM can rely only on individual assessment (based on an effective concentration before pregnancy) and remains reserved only to unexpected situations such as signs of toxicity or unexplained inefficiency.

Identificador

http://serval.unil.ch/?id=serval:BIB_18592A49D874

isbn:0040-5957 (Print)

pmid:25011648

doi:10.2515/therapie/2014026

isiid:000339275900004

Idioma(s)

fr

Direitos

info:eu-repo/semantics/openAccess

Fonte

Therapie, vol. 69, no. 3, pp. 223-234

Palavras-Chave #pregnancy; pharmacokinetics; therapeutic drug monitoring; treatment outcome; teratogen
Tipo

info:eu-repo/semantics/review

article